SEC Filings
Amphastar Sales Climb 8% — But Lower Prices And Factory Costs Squeeze Margins
Record BAQSIMI and Primatene MIST sales supported growth, while the board added $50 million to its buyback authorization.
Amphastar Pharmaceuticals (AMPH) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Record BAQSIMI and Primatene MIST sales supported growth, while the board added $50 million to its buyback authorization.
Earnings
The CFO says the duplicate-discount fix is nearly maxed out, and this year's 3% price increase does not close the gap.